Research Article
The Relationship of Antibodies to Modified Citrullinated Vimentin and Markers of Bone and Cartilage Destruction in Rheumatoid Arthritis
Table 1
Demographic, clinical, and laboratory data for the group of RA patients (
).
| | Parameters | Value |
| | Number of females/males | 93/21 | | Age, years Me (IQR) | 53.0 (42.0–60.0) | | Disease duration, months, Me (IQR) | 60.0 (28.0–108.0) | | X-ray phase, (%) | | | I/II/III/IV | 2 (1.8)/50 (43.9)/46 (40.4)/16 (14) | | DAS 28, Me (IQR) | 5.9 (5.2–6.7) | | DMARD use, (%) | 109 (95.6) | |
MTX use, (%) | 86 (75.4) | | ESR, mm/hr Me (IQR) | 38.0 (29.0–60.0) | | CRP, mg/L Me (IQR) | 22.4 (12.7–47.2) | | IgM RF positivity, (%) | 94 (82.5) | | Anti-CCP positivity, (%) | 95 (83.3) | | Anti-MCV positivity (), (%) | 92 (86.9) |
|
|
